Eli Lilly : LLY

All Eli Lilly Articles

652 Articles

David Beren | Feb 25, 2026 at 7:08 AM EST

Novo Nordisk Cuts Wegovy Prices in Half While Its Stock Sits Near a 52-Week Low

After finding itself some unwanted attention this week, Novo Nordisk (NYSE:NVO | NVO Price Prediction) has dropped 22% in the…

David Beren | Feb 16, 2026 at 2:00 PM EST

Why Eli Lilly’s $1 Billion AI Bet Could Reshape Drug Discovery

Editor’s note: A prior version of this article stated Eli Lilly and Nvidia had funded a supercomputer, when the commitment…

Joey Frenette | Feb 12, 2026 at 10:00 AM EST

2 Biotech Stocks to Buy as AI Drug Discovery Lifts Off

AI-assisted drug discovery isn’t just science fiction anymore, especially as biotechnology and biopharma firms embrace the AI age. Undoubtedly, it’s…

Joel South | Feb 12, 2026 at 8:20 AM EST

Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2026-2030 (Jan 2026)

24/7 Wall St. provides estimates for future stock prices of Eli Lilly from 2026 to 2030 based on projected revenue…

John Seetoo | Feb 11, 2026 at 7:15 AM EST

GLP-1 Lawsuits Are the Black Swan Risk Investors Aren’t Watching

One of the biggest trends in the fight against obesity has been the explosion in popularity of GLP-1 medications. Created…

Rich Duprey | Feb 4, 2026 at 2:39 PM EST

Eli Lilly Is Dominating the GLP-1 Wars as Novo Nordisk Sales Tank

The rivalry in the GLP-1 market between pharmaceutical leaders Eli Lilly (NYSE:LLY | LLY Price Prediction) and Novo Nordisk (NYSE:NVO)…

Joel South | Feb 2, 2026 at 11:40 AM EST

Merck Reports Earnings Tuesday Morning After Gaining 13% Over the Past Year

Merck & Co. reports Q4 2025 earnings on Tuesday, Feb. 3, 2026, before market open. Wall Street expects earnings of…

Michael Williams | Jan 23, 2026 at 2:06 PM EST

Investor Bets $100k On David v Goliath Matchup With Altimmune and Eli Lilly

Shares of Altimmune (NASDAQ:ALT) surged 35.4% over the past week, coinciding with a dramatic shift in retail investor sentiment on…

Austin Smith | Jan 23, 2026 at 10:36 AM EST

VanEck Pharmaceutical Fund Bets Big on Weight-Loss Drug Market Approaching $150 Billion

The VanEck Pharmaceutical ETF (NYSEARCA:PPH) has surged 26% over the past year, driven almost entirely by the weight-loss drug revolution.…

Joey Frenette | Jan 22, 2026 at 1:17 PM EST

Is the 2026 Market Rotation Already Underway? Here’s What Could Lead After the Magnificent 7

It feels like a great rotation out of the Magnificent Seven has already kicked off just over a quarter ago.…

Trey Thoelcke | Jan 19, 2026 at 8:45 AM EST

Huge Insider Buying Now at This Insurance Giant and 2 Biotechs

Alumis, Aktis Oncology, and W.R. Berkley saw the most prominent insider buying of the past week. There were a handful…

Rich Duprey | Jan 12, 2026 at 12:48 PM EST

Eli Lilly and Nvidia Make $1 Billion AI Bet to Revolutionize Pharma’s Future

One of the major promises of artificial intelligence (AI) is its role in speeding up drug discovery. AI can process…

William Temple | Jan 10, 2026 at 8:59 AM EST

The GLP-1 Blockbuster Maker Widens Its Lead as the Diversified Healthcare Giant Posts Steady Growth

Eli Lilly (NYSE: LLY | LLY Price Prediction) and Johnson & Johnson (NYSE: JNJ) both delivered strong third-quarter results, but…

Rich Duprey | Dec 28, 2025 at 7:29 AM EST

Why Eli Lilly Is the Unexpected Must-Buy Dividend Powerhouse to Own in 2026

Dividend growth investing builds long-term wealth for retirement by focusing on companies that consistently increase payouts. These stocks provide rising…

Rich Duprey | Dec 19, 2025 at 10:52 AM EST

Did Eli Lilly Just Find the Holy Grail of Weight Loss?

Eli Lilly (NYSE:LLY | LLY Price Prediction) is rapidly establishing itself as the leader in GLP-1 treatments for weight loss.…

1 … 3 4 5 6 7 … 44

Eli Lilly : LLY

All Eli Lilly Articles

Novo Nordisk Cuts Wegovy Prices in Half While Its Stock Sits Near a 52-Week Low

Why Eli Lilly’s $1 Billion AI Bet Could Reshape Drug Discovery

2 Biotech Stocks to Buy as AI Drug Discovery Lifts Off

Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2026-2030 (Jan 2026)

GLP-1 Lawsuits Are the Black Swan Risk Investors Aren’t Watching

Eli Lilly Is Dominating the GLP-1 Wars as Novo Nordisk Sales Tank

Merck Reports Earnings Tuesday Morning After Gaining 13% Over the Past Year

Investor Bets $100k On David v Goliath Matchup With Altimmune and Eli Lilly

VanEck Pharmaceutical Fund Bets Big on Weight-Loss Drug Market Approaching $150 Billion

Is the 2026 Market Rotation Already Underway? Here’s What Could Lead After the Magnificent 7

Huge Insider Buying Now at This Insurance Giant and 2 Biotechs

Eli Lilly and Nvidia Make $1 Billion AI Bet to Revolutionize Pharma’s Future

The GLP-1 Blockbuster Maker Widens Its Lead as the Diversified Healthcare Giant Posts Steady Growth

Why Eli Lilly Is the Unexpected Must-Buy Dividend Powerhouse to Own in 2026

Did Eli Lilly Just Find the Holy Grail of Weight Loss?

Why Mario Gabelli Is Smiling — His ETF Delivers 7.5% in Monthly Dividends in 2 Must-Own Sectors

Apple vs Microsoft: Which Is the Better Dip Buy Right Now?

The Homebody Portfolio: How Much Does Retirement Cost When You Never Leave Chicago?

The Homebody Portfolio: How Much Does Retirement Cost When You Never Leave Chicago?

Retired Firefighter With $810,000 Discovers Pension Just Triggered an IRMAA Surprise

BlackBerry, IBM, and Nokia Are All Trying to Come Back. History Says Only One Survives

JEPI’s Covered-Call Strategy Could Pay You $100,000/Year for Doing Nothing

Eli Lilly : LLY

All Eli Lilly Articles

Novo Nordisk Cuts Wegovy Prices in Half While Its Stock Sits Near a 52-Week Low

Why Eli Lilly’s $1 Billion AI Bet Could Reshape Drug Discovery

2 Biotech Stocks to Buy as AI Drug Discovery Lifts Off

Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2026-2030 (Jan 2026)

GLP-1 Lawsuits Are the Black Swan Risk Investors Aren’t Watching

Eli Lilly Is Dominating the GLP-1 Wars as Novo Nordisk Sales Tank

Merck Reports Earnings Tuesday Morning After Gaining 13% Over the Past Year

Investor Bets $100k On David v Goliath Matchup With Altimmune and Eli Lilly

VanEck Pharmaceutical Fund Bets Big on Weight-Loss Drug Market Approaching $150 Billion

Is the 2026 Market Rotation Already Underway? Here’s What Could Lead After the Magnificent 7

Huge Insider Buying Now at This Insurance Giant and 2 Biotechs

Eli Lilly and Nvidia Make $1 Billion AI Bet to Revolutionize Pharma’s Future

The GLP-1 Blockbuster Maker Widens Its Lead as the Diversified Healthcare Giant Posts Steady Growth

Why Eli Lilly Is the Unexpected Must-Buy Dividend Powerhouse to Own in 2026

Did Eli Lilly Just Find the Holy Grail of Weight Loss?

Why Mario Gabelli Is Smiling — His ETF Delivers 7.5% in Monthly Dividends in 2 Must-Own Sectors

Apple vs Microsoft: Which Is the Better Dip Buy Right Now?

The Homebody Portfolio: How Much Does Retirement Cost When You Never Leave Chicago?

Featured Reads

The Homebody Portfolio: How Much Does Retirement Cost When You Never Leave Chicago?

Retired Firefighter With $810,000 Discovers Pension Just Triggered an IRMAA Surprise